Dopamine versus norepinephrine in the treatment of septic shock: A meta-analysis*

Critical Care Medicine

Volumn 40, Issue 3, 2012, Pages 725-730

  De Backer, Daniel ^a   Aldecoa, Cesar ^b   Njimi, Hassane ^a   Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

^b HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

Author keywords

adrenergic agents; adverse effects; mortality; outcome; vasopressor

Indexed keywords

DOPAMINE; NORADRENALIN;

ARTICLE; DRUG EFFECT; HEART ARRHYTHMIA; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SEPTIC SHOCK; TREATMENT OUTCOME;

ADRENERGIC ALPHA-AGONISTS; DOPAMINE; DOPAMINE AGENTS; HUMANS; NOREPINEPHRINE; SHOCK, SEPTIC;

EID: 84857602458     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31823778ee     Document Type: Article

References (30)

1. Varpula M, Tallgren M, Saukkonen K, et al: Hemodynamic variables related to outcome in septic shock. Intensive Care Med 2005;31:1066-1071
2. Marchick MR, Kline JA, Jones AE: The significance of non-sustained hypotension in emergency department patients with sepsis. Intensive Care Med 2009;35:1261-1264
3. Sakr Y, Reinhart K, Vincent JL, et al: Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med 2006;34:589-597
4. van der Poll T, Coyle SM, Barbosa K, et al: Epinephrine inhibits tumor necrosis factoralpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996;97:713-719
5. Bellomo R, Chapman M, Finfer S, et al: Lowdose dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000;356:2139-2143
6. Van den Berghe G, de Zegher F: Anterior pituitary function during critical illness and dopamine treatment. Crit Care Med 1996;24:1580-1590
7. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 1999;27:639-660
8. Vincent JL, International Sepsis Forum: Hemodynamic support in septic shock. Intensive Care Med 2001;27:S80-S92
9. Antman EM, Anbe DT, Armstrong PW, et al: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004;110:e82-e292
10. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008;34:17-60
11. Martin C, Viviand X, Leone M, et al: Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000;28:2758-2765
12. Boulain T, Runge I, Bercault N, et al: Dopamine therapy in septic shock: Detrimental effect on survival? J Crit Care 2009;24:575-582
13. Povoa PR, Carneiro AH, Ribeiro OS, et al: Influence of vasopressor agent in septic shock mortality. Results from the Portuguese Community-Acquired Sepsis Study (SACiUCI study). Crit Care Med 2009;37:410-416
14. Mullner M, Urbanek B, Havel C, et al: Vasopressors for shock. Cochrane Database Syst Rev 2004; CD003709
15. De Backer D, Biston P, Devriendt J, et al: Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362:779-789
16. Patel GP, Grahe JS, Sperry M, et al: Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock 2010;33:375-380
17. Vasu TS, Cavallazzi R, Hirani A, et al: Norepinephrine or dopamine for septic shock: A systematic review of randomized clinical trials. J Intensive Care Med 2011
18. Havel C, Arrich J, Losert H, et al: Vasopressors for hypotensive shock. Cochrane Database Syst Rev 2011;5:CD003709
19. Higgins J P T, Green S: Cochrane Handbook for Systematic Reviews of Interventions. 2011; Version 5.1.0
20. Liberati A, Altman DG, Tetzlaff J, et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100
21. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558
22. Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634
23. Der Simonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188
24. Hall LG, Oyen LJ, Taner CB, et al: Fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock. Pharmacotherapy 2004;24:1002-1012
25. Mathur SM, Dhunna R, Chakraborty A: Comparison of dopamine and norepinephrine in the management of septic shock using impedance cardiography. Ind J Crit Care Med 2007;11:186-191
26. Morimatsu H, Singh K, Uchino S, et al: Early and exclusive use of norepinephrine in septic shock. Resuscitation 2004;62:249-254
27. Martin C, Papazian L, Perrin G, et al: Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993;103:1826-1831
28. Levy B, Dusang B, Annane D, et al: Cardiovascular response to dopamine and early prediction of outcome. A prospective multicenter study. Crit Care Med 2005;33:2172-2177
29. Ruokonen E, Takala J, Kari A, et al: Regional blood flow and oxygen transport in septic shock. Crit Care Med 1993;21:1296-1303
30. Marik PE, Mohedin M: The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994;272:1354-1357 730